lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1 row where filing_uuid = "ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: received_date (date)

issue_code 1

filing_year 1

filing_period 1

id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2423528 RED+BLUE STRATEGIES ccdde4c8-5ef7-4c04-9433-ccd4e8f732d8 Q1 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2020 first_quarter PHA H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-04-12T14:44:52.997000-04:00

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options: 

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);